M. V. Van Glabbeke

发表

New guidelines to evaluate the response to treatment in solid tumors

M. van Glabbeke, M. Christian, E. Eisenhauer, 2000, Journal of the National Cancer Institute.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

M Van Glabbeke, J Verweij, M. van Glabbeke, 2000, Journal of the National Cancer Institute.

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

J. Blay, M. van Glabbeke, J. Verweij, 2009, Cancer research.

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.

M. van Glabbeke, M. Glabbeke, A. Cesne, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

J. Blay, M. van Glabbeke, A. Hagemeijer, 2006, European journal of cancer.

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

M. van Glabbeke, R. Sciot, J. Verweij, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.

A. Hagenbeek, M. van Glabbeke, S. Pittaluga, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].

M. van Glabbeke, E. Eisenhauer, M. Glabbeke, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

M. van Glabbeke, J. Bourhis, M. Bolla, 2004, The New England journal of medicine.

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

M. van Glabbeke, J. Armand, P. Fumoleau, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice].

J. Horiot, M. Piérart, M. van Glabbeke, 1996, Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique.

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

J. Blay, M. van Glabbeke, J. Verweij, 2005, European journal of cancer.

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

J. Blay, M. van Glabbeke, R. Sciot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2003, European journal of cancer.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

E. Kimby, A. Hagenbeek, M. van Glabbeke, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Max Wolf, Ivana Teodorovic, Randy D Gascoyne, 2006, Blood.

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours

J. Blay, M. van Glabbeke, R. Sciot, 2010, Histopathology.

A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.

J W Oosterhuis, J Verweij, M. van Glabbeke, 2001, European journal of cancer.

Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.

J. Baars, M. van Glabbeke, E. Noordijk, 2006, Haematologica.

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom

S. Sleijfer, J. Blay, S. Rodenhuis, 2010, European journal of cancer.

Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.

J. Blay, M. van Glabbeke, P. Hohenberger, 2013, European journal of cancer.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Patrick Schöffski, Jean-Yves Blay, Françoise Collin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

J. Blay, S. Rodenhuis, M. van Glabbeke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2002, European journal of cancer.

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2002, European journal of cancer.

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of

J. Blay, S. Rodenhuis, M. van Glabbeke, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2000, Sarcoma.

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

O. S. Nielsen, M. van Glabbeke, D. Crowther, 1998, British Journal of Cancer.

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2000, European journal of cancer.

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

M. van Glabbeke, R. Sciot, A. Lazar, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.

M. van Glabbeke, M. J. van den Bent, M. Taphoorn, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

Jacques Bernier, Michel Bolla, Mahmut Ozsahin, 2004, The New England journal of medicine.

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

M. van Glabbeke, J. Klijn, M. Nooij, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of carboplatin in advanced or metastatic stomach cancer.

F. Cavalli, M. van Glabbeke, S. Kaye, 1987, European journal of cancer & clinical oncology.

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

M. van Glabbeke, M. Piccart, D. Lacombe, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.

Sigrid Stroobants, O. S. Nielsen, Sasa Dimitrijevic, 2002, European journal of cancer.

Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group.

E. Bröcker, L. Kangas, U. Kleeberg, 1993, Melanoma research.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S. Sleijfer, F. Collin, M. van Glabbeke, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy.

M. van Glabbeke, S. Monfardini, S. Gundersen, 1988, European journal of cancer & clinical oncology.

Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck.

M. van Glabbeke, S. Monfardini, H. Pinedo, 1987, European journal of cancer & clinical oncology.

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).

J. Blay, M. van Glabbeke, J. Verweij, 2006, European journal of cancer.

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

Daphne de Jong, Anton Hagenbeek, J. Raemaekers, 2009, Haematologica.

Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors

J. Blay, M. van Glabbeke, R. Sciot, 2009, Clinical Cancer Research.

Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.

M. Piérart, M. van Glabbeke, R. Mirimanoff, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.

J. Baars, M. van Glabbeke, S. le Cessie, 2006, Blood.

Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.

M. van Glabbeke, P. Hérait, J. Armand, 1992, European journal of cancer.

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

J. Blay, M. van Glabbeke, F. Bertucci, 2012, Clinical Cancer Research.

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

M. van Glabbeke, M. Sydes, M. Nooij, 2007, Journal of the National Cancer Institute.

Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, P. Woll, 1991, European journal of cancer.

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.

M. van Glabbeke, J. Verweij, A. V. van Oosterom, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

Philippe Cornu, A. Karim, M. Piérart, 2002, International journal of radiation oncology, biology, physics.

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

A. Karim, B. Maat, R. Hatlevoll, 1996, International journal of radiation oncology, biology, physics.

A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.

J. Blay, M. van Glabbeke, J. Verweij, 2008, The oncologist.

Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.

J. Baars, M. van Glabbeke, E. Noordijk, 2004, European journal of cancer.

Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group.

M. van Glabbeke, C. de Wolf‐Peeters, B. D. de Pauw, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study.

M. van Glabbeke, D. Machin, M. Nooij, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?

M Van Glabbeke, M. van Glabbeke, J. Armand, 2002, European journal of cancer.

EORTC trial non-Hodgkin lymphomas.

M. van Glabbeke, N. Duez, M. Hayat, 1987, European journal of cancer & clinical oncology.

Prognostic factors in non-Hodgkin's lymphoma.

M. van Glabbeke, M. Tubiana, J. Cosset, 1986, International journal of radiation oncology, biology, physics.

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.

E. Kimby, A. Hagenbeek, M. van Glabbeke, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2002, European journal of cancer.

Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.

J. Raemaekers, J. Baars, M. van Glabbeke, 2005, Clinical lymphoma & myeloma.

ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).

J. Horiot, H. Hamers, M. Piérart, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.

J. Horiot, M. van Glabbeke, S. Schraub, 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.

J. Horiot, M. van Glabbeke, S. Schraub, 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey.

H. Bartelink, K. Ang, J. Horiot, 1988, Frontiers of radiation therapy and oncology.

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.

J. Blay, F. Collin, M. van Glabbeke, 2008, European journal of cancer.

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Blay, M. van Glabbeke, J. Verweij, 2007, European journal of cancer.

Age has no impact on acute and late toxicity of curative thoracic radiotherapy.

M. van Glabbeke, A. Gregor, P. Scalliet, 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group.

F. Cavalli, P. Dombernowsky, S. Gundersen, 1989, European Journal of Cancer and Clinical Oncology.

A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI).

M. van Glabbeke, R. Souhami, D. Machin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.

M. van Glabbeke, P. Therasse, J. Verweij, 2005, European journal of cancer.

Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.

M. van Glabbeke, M. Sydes, A. McTiernan, 2011, European journal of cancer.

Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).

F. Cavalli, M. van Glabbeke, M. Glabbeke, 1988, European journal of cancer & clinical oncology.

Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial?

J. Blay, J. Verweij, M. Glabbeke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

M. van Glabbeke, M. Sydes, A. McTiernan, 2012, European Journal of Cancer.

Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials Group.

M. van Glabbeke, V. Bramwell, W. W. ten Bokkel Huinink, 1984, European journal of cancer & clinical oncology.

Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group.

F. Cavalli, M. van Glabbeke, H. Hansen, 1983, European journal of cancer & clinical oncology.

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. van Glabbeke, M. Glabbeke, P. Fumoleau, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, S. Rodenhuis, M. van Glabbeke, 1999, European journal of cancer.

ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.

J. Horiot, H. Hamers, M. Piérart, 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Interferon‐α‐2a with or without 13‐cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma

M. van Glabbeke, S. Fosså, M. Fey, 2004 .

Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

J. Blay, M. van Glabbeke, J. Verweij, 2008, Clinical Cancer Research.

Phase II studies on prostate cancer.

M. van Glabbeke, C. Busch, J. Johansson, 1997, Urology.

Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

O. S. Nielsen, M. van Glabbeke, S. Gwyther, 2000, Anti-cancer drugs.

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.

M. van Glabbeke, J. V. van Meerbeeck, R. Sylvester, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.

G. Giaccone, M. van Glabbeke, T. Sutedja, 1997, European journal of cancer.

Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.

J. Baars, E. Noordijk, H. Kluin-Nelemans, 2006, Haematologica.

Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.

E. Kimby, A. Hagenbeek, R. Marcus, 2004 .

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial – Intergroup Collaborative Study

A. Hagenbeek, M. van Glabbeke, M. V. van Oers, 2002, Annals of Hematology.

Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.

A. Hagenbeek, K. Maclennan, M. van Glabbeke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.

J. Baars, M. van Glabbeke, E. Noordijk, 2006, International journal of radiation oncology, biology, physics.

Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group.

F. Cavalli, M. van Glabbeke, S. Monfardini, 1996, Oncology.

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

J. Blay, F. Bertucci, J. Verweij, 2012, Clinical Cancer Research.

An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.

M. van Glabbeke, H. Earl, J. Armand, 1984, European journal of cancer & clinical oncology.

Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas. A pilot feasibility study of the Radiotherapy Group of the EORTC.

K. Ang, J. Horiot, M. van Glabbeke, 1982, International journal of radiation oncology, biology, physics.

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

J. Raemaekers, A. Hagenbeek, D. de Jong, 2009, Haematologica.

Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

J. Blay, J. Verweij, H. Guchelaar, 2008, Clinical Cancer Research.

Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG.

J. Blay, M. van Glabbeke, J. Verweij, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Comparison of two Short Intensive Chemotherapy Regimens in Children and Young Adults With Osteosarcoma: Results in Patients With Metastases: A Study of the European Osteosarcoma Intergroup

M. van Glabbeke, R. Souhami, D. Machin, 1997, Sarcoma.

Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2006, European journal of cancer.

Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.

S. Kaye, P. D. De Mulder, W. W. ten Bokkel Huinink, 1990, Journal of biological response modifiers.

Present status of EORTC trials of hyperfractionated and accelerated radiotherapy on head and neck carcinoma.

J. Horiot, M. Piérart, M. van Glabbeke, 1994, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents.

O. Dalesio, M. van Glabbeke, J. Wanders, 1991, European journal of cancer.